Urovan­t's over­ac­tive blad­der drug scores in mid-stage tri­al

Urovant Sci­ences said its ex­per­i­men­tal over­ac­tive blad­der drug vibegron im­proved symp­toms in a large mid-stage study, a wel­come sig­nal for the com­pa­ny as it eval­u­ates the drug fur­ther in a phase III ini­ti­at­ed ear­li­er this year.

The phase IIb two-stage tri­al en­rolled more than 1,300 pa­tients with OAB symp­toms. In the first stage, pa­tients ei­ther re­ceived once-dai­ly oral vibegron (3 mg, 15 mg, 50 mg or 100 mg), the uri­nary in­con­ti­nence drug toltero­dine (4 mg); or a place­bo for eight weeks. In the sec­ond stage, pa­tients were giv­en ei­ther vibegron (100 mg); toltero­dine (4 mg); a com­bi­na­tion vibegron (100 mg) and toltero­dine (4 mg); or place­bo for four weeks. The ob­jec­tive of the study was to eval­u­ate the safe­ty and ef­fi­ca­cy of vibegron as a once-dai­ly oral treat­ment for OAB pa­tients, re­gard­less of urge in­con­ti­nence.

Kei­th Katkin, Urovant CEO

Pa­tients giv­en the high­er dos­es of vibegron (50 mg and 100 mg) ex­pe­ri­enced sta­tis­ti­cal­ly sig­nif­i­cant de­creas­es in the dai­ly rate of uri­na­tion (p=0.007 and p<0.001 re­spec­tive­ly), ur­gency uri­nary in­con­ti­nence episodes (p<0.001 and p<0.001 re­spec­tive­ly), to­tal in­con­ti­nence episodes (p=0.005 and p=0.007) and ur­gency episodes (p=0.024 and p<0.001) at week 8. In the sec­ond tranche of the study, the ef­fi­ca­cy of vibegron monother­a­py on the pri­ma­ry end­point — re­duc­tion in uri­na­tion — was al­so sta­tis­ti­cal­ly sig­nif­i­cant, the com­pa­ny said.

Toltero­dine, sold as De­trol by Pfiz­er $PFE in the Unit­ed States, be­longs to a class of drugs called an­timus­carinics that are de­signed to in­hib­it mus­cle con­trac­ture and have been the on­ly avail­able treat­ments for decades. But they’re not de­signed specif­i­cal­ly for the blad­der and are as­so­ci­at­ed with a host of un­pleas­ant ad­verse-ef­fects, mak­ing them an un­pop­u­lar choice with pa­tients, es­pe­cial­ly in the el­der­ly.

Tri­al da­ta in­di­cat­ed that the mag­ni­tude of max­i­mal re­spons­es with the two high­er vibegron dos­es was of­ten nu­mer­i­cal­ly greater than toltero­dine, re­searchers wrote in the jour­nal Eu­ro­pean Urol­o­gy. “In ad­di­tion, these re­sults pro­vide the proof of con­cept that con­comi­tant dos­ing of vibegron and an an­timus­carinic can pro­duce mod­est symp­tom im­prove­ment ver­sus an an­timus­carinic alone”, they not­ed.

In the tri­al, all vibegron dos­es were well tol­er­at­ed. The in­ci­dence of dry mouth was high­er with pa­tients giv­en toltero­dine than those on vibegron monother­a­py, Urovant said.

The ex­act cause of OAB is un­known, which makes it dif­fi­cult to treat. More than 30 mil­lion over the age of 40 suf­fer symp­toms in the Unit­ed States ac­cord­ing to Urovant $UROV.

End­points News / Pharm­cube BI­IS18 Con­fer­ence in Shang­hai

Click on the im­age to see the full-sized ver­sion

Urovant is one of Vivek Ra­maswamy’s many “vants”, which are sub­sidiaries un­der the con­glom­er­ate Roivant Sci­ences brand. Last week Ra­maswamy told End­points News at the #BI­IS18 sum­mit that his strat­e­gy can be un­der­stood as an “Al­pha­bet for health­care”, a ref­er­ence to Google co-founder Lar­ry Page’s play­book of set­ting loose Google, YouTube, and even com­pa­nies like Cal­i­co and Ver­i­ly as se­mi-au­tonomous units that are led by the moth­er­ship. To date, Ra­maswamy has raised $3 bil­lion for his com­pa­nies and vibegron is one of 34 pro­grams in the “vant” clin­ic.

Urovant in-li­censed the glob­al rights, in­clud­ing Japan, to vibegron — an oral be­ta-3 adren­er­gic ag­o­nist — from Mer­ck $MRK. Vibegron is al­so be­ing test­ed for the treat­ment of OAB in men with be­nign pro­sta­t­ic hy­per­pla­sia and the treat­ment of pain as­so­ci­at­ed with ir­ri­ta­ble bow­el syn­drome. Mean­while, Urovant’s sec­ond ex­per­i­men­tal treat­ment, hMaxi-K, is a gene ther­a­py for pa­tients with OAB symp­toms who have failed oral phar­ma­co­log­ic ther­a­py.

UP­DAT­ED: In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

Apart from revealing its checkpoint inhibitor Opdivo blew a big liver cancer study on Monday, Bristol-Myers Squibb said its plans to swallow Celgene will require the sale of blockbuster psoriasis treatment Otezla to keep the Federal Trade Commission (FTC) at bay.

The announcement — which has potentially delayed the completion of the takeover to early 2020 — irked investors, triggering the New York-based drugmaker’s shares to tumble Monday morning in premarket trading.

Celgene’s Otezla, approved in 2014 for psoriasis and psoriatic arthritis, is a rising star. It generated global sales of $1.6 billion last year, up from the nearly $1.3 billion in 2017. Apart from the partial overlap of Bristol-Myers injectable Orencia, the company’s rival oral TYK2 psoriasis drug is in late-stage development, after the firm posted encouraging mid-stage data on the drug, BMS-986165, last fall. With Monday’s decision, it appears Bristol-Myers is favoring its experimental drug, and discounting Otezla’s future.

The move blindsided some analysts. Credit Suisse’s Vamil Divan noted just days ago:

Endpoints News

Basic subscription required

Unlock this story instantly and join 53,400+ biopharma pros reading Endpoints daily — and it's free.

Novotech CEO Dr. John Moller

Novotech CRO Award­ed Frost & Sul­li­van Best Biotech CRO Asia-Pa­cif­ic 2019

Known in the in­dus­try as the Asia-Pa­cif­ic CRO, Novotech is now lead CRO ser­vices provider for the grow­ing num­ber of in­ter­na­tion­al biotechs se­lect­ing the re­gion for their stud­ies.

Re­flect­ing this Asia-Pa­cif­ic growth, Novotech staff num­bers are up 20% since De­cem­ber 2018 to 600 in-house clin­i­cal re­search peo­ple across a full range of ser­vices, across the re­gion.

Novotech’s ca­pa­bil­i­ties have been rec­og­nized by an­a­lysts like Frost & Sul­li­van, most re­cent­ly with the pres­ti­gious Asia-Pa­cif­ic CRO Biotech of the year award for best prac­tices in clin­i­cal re­search for biotechs for the fifth year. See oth­er awards here.

Fol­low­ing news of job cuts in Eu­ro­pean R&D ops, Sanofi con­firms it’s of­fer­ing US work­ers an 'ear­ly ex­it'

Ear­li­er in the week we learned that Sanofi was bring­ing out the bud­get ax to trim 466 R&D jobs in Eu­rope, re­tool­ing its ap­proach to car­dio as re­search chief John Reed beefed up their work in can­cer and gene ther­a­pies. And we’re end­ing the week with news that the phar­ma gi­ant has al­so been qui­et­ly re­duc­ing staff in the US, tar­get­ing hun­dreds of jobs as the com­pa­ny push­es vol­un­tary buy­outs with a fo­cus on R&D sup­port ser­vices.

Suf­fer­ing No­var­tis part­ner Cona­tus is pack­ing it in on NASH af­ter a se­ries of un­for­tu­nate tri­al events

The NASH par­ty is over at No­var­tis-backed Cona­tus. And this time they’re turn­ing off the lights.

More than 2 years af­ter No­var­tis sur­prised the biotech in­vest­ment com­mu­ni­ty with its $50 mil­lion up­front and promise of R&D sup­port to part­ner with the lit­tle biotech on NASH — ig­nit­ing a light­ning strike for the share price — Cona­tus $CNAT is back with the lat­est bit­ter tale to tell about em­ri­c­as­an, which once in­spired con­fi­dence at the phar­ma gi­ant.

Bet­ter than Am­bi­en? Min­er­va soars on PhI­Ib up­date on sel­torex­ant for in­som­nia

A month af­ter roil­ing in­vestors with what skep­tics dis­missed as cher­ry pick­ing of its de­pres­sion da­ta, Min­er­va is back with a clean slate of da­ta from its Phase IIb in­som­nia tri­al.

In a de­tailed up­date, the Waltham, MA-based biotech said sel­torex­ant (MIN-202) hit both the pri­ma­ry and sev­er­al sec­ondary end­points, ef­fec­tive­ly im­prov­ing sleep in­duc­tion and pro­long­ing sleep du­ra­tion. In­ves­ti­ga­tors made a point to note that the ef­fects were con­sis­tent across the adult and el­der­ly pop­u­la­tions, with the lat­ter more prone to the sleep dis­or­der.

Gene ther­a­py biotech sees its stock rock­et high­er on promis­ing re­sults for rare cas­es of but­ter­fly dis­ease

Shares of Krys­tal Biotech took off this morn­ing $KRYS af­ter the lit­tle biotech re­port­ed promis­ing re­sults from its gene ther­a­py to treat a rare skin dis­ease called epi­der­mol­y­sis bul­losa.

Fo­cus­ing on an up­date with 4 new pa­tients, re­searchers spot­light­ed the suc­cess of KB103 in clos­ing some stub­born wounds. Krys­tal says that of 4 re­cur­ring and 2 chron­ic skin wounds treat­ed with the gene ther­a­py, the KB103 group saw the clo­sure of 5. The 6th — a chron­ic wound, de­fined as a wound that had re­mained open for more than 12 weeks — was par­tial­ly closed. That brings the to­tal so far to 8 treat­ed wounds, with 7 clo­sures.

Ab­b­Vie gets a green light to re­sume re­cruit­ing pa­tients for one myelo­ma study — but Ven­clex­ta re­mains un­der a cloud

Three months af­ter reg­u­la­tors at the FDA forced Ab­b­Vie to halt en­rolling pa­tients in its tri­als of a com­bi­na­tion us­ing Ven­clex­ta (vene­to­clax) to treat drug-re­sis­tant cas­es of mul­ti­ple myelo­ma, the agency has green-light­ed the re­sump­tion of one of those stud­ies, while keep­ing the rest on the side­lines.

The CANO­VA (M13-494) study can now get back in busi­ness re­cruit­ing pa­tients to test the drug for a pop­u­la­tion that shares a par­tic­u­lar ge­net­ic bio­mark­er. To get that per­mis­sion, Ab­b­Vie — which is part­nered with Roche on this pro­gram — was forced to re­vise the pro­to­col, mak­ing un­spec­i­fied changes in­volv­ing risk mit­i­ga­tion mea­sures, pro­to­col-spec­i­fied guide­lines and an up­dat­ed fu­til­i­ty cri­te­ria.

Bris­tol-My­ers star Op­di­vo fails sur­vival test in a matchup with Nex­avar aimed at shak­ing up the big HCC mar­ket

Bris­tol-My­ers Squibb has suf­fered an­oth­er painful set­back in its years-long quest to ex­pand the reach of Op­di­vo. The phar­ma gi­ant this morn­ing not­ed that their Check­mate-459 study com­par­ing Op­di­vo with Bay­er’s Nex­avar in front­line cas­es of he­pa­to­cel­lu­lar car­ci­no­ma — the most com­mon form of liv­er can­cer — failed to hit the pri­ma­ry end­point on over­all sur­vival.

This was a sig­nif­i­cant mile­stone in Bris­tol-My­ers’ tal­ly of PD-1 cat­a­lysts this year. Nex­avar (so­rafenib) has been the stan­dard of care in front­line HCC for the past decade, though Op­di­vo has been mak­ing head­way in sec­ond-line HCC cas­es, where it’s go­ing toe-to-toe with Bay­er’s Sti­var­ga (re­go­rafenib) af­ter re­cent ap­provals shook up the mar­ket.

Dean Hum. Nasdaq via YouTube

Gen­fit goes to Chi­na with a deal worth up to $228M for NASH drug

Fresh off the high of its Nas­daq IPO de­but, and the low of com­par­isons to Cymabay — whose NASH drug re­cent­ly stum­bled — Gen­fit on Mon­day un­veiled an up to $228 mil­lion deal with transpa­cif­ic biotech Terns Phar­ma­ceu­ti­cals to de­vel­op its flag­ship ex­per­i­men­tal liv­er drug — elafi­bra­nor — in Greater Chi­na.

The deal comes more than a week af­ter Gen­fit $GN­FT is­sued a fiery de­fense of its dual PPAR ag­o­nist elafi­bra­nor, when com­peti­tor Cymabay’s PPARδ ag­o­nist, se­ladel­par, fiz­zled in a snap­shot of da­ta from an on­go­ing mid-stage tri­al. The main goal at the end of 12 weeks was for se­ladel­par to in­duce a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in liv­er fat con­tent, but da­ta showed that pa­tients on the place­bo ac­tu­al­ly per­formed bet­ter.